Rezolute (RZLT) said the US Food and Drug Administration granted breakthrough therapy designation for its investigational treatment for ersodetug, a treatment for hypoglycemia caused by tumor hyperinsulinism.
The designation was awarded based on clinical trial data across an overall development program that showed the treatment works in a way that directly targets the underlying cause of the tumor hyperinsulinism, the company said Monday in a statement.
Rezolute plans to start a registrational study of the drug in patients with tumor hyperinsulinism in the middle of this year with topline results expected in H2 2026.
The company is also evaluating ersodetug for the treatment of hypoglycemia caused by congenital hyperinsulinism in a Phase 3 trial.
Price: 4.01, Change: +0.01, Percent Change: +0.25
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.